NJOY Leadership

Extensive experience in nicotine and non-nicotine new product development, tobacco control policy, and related regulation in the international healthcare and e-vapor industries spanning ~ 25 years. Beginning in the pharmaceutical industry with nicotine replacement therapy/smoking cessation products in 1992, he left Johnson & Johnson to join NJOY in 2013 to lead the regulatory affairs, quality & compliance function for the company and prepare for regulation by FDA and other regulatory agencies in the US and abroad. In addition to multiple interactions with FDA while at NJOY, David co-led NJOY’s engagement with the National Institute of Drug Abuse (NIDA) on its Small Business Innovation Research (SBIR) award for NJOY to develop an Electronic Nicotine Delivery System (ENDS) for use for clinical research in smoking cessation, leading to the establishment of the first FDA Drug Master File (DMF) for ENDS products. In late 2016, David co-founded and was President of Reveritas Group, a multi-partner consultancy firm of specialists and preferred providers formed to aid ENDS companies navigate all aspects of FDA’s Premarket Tobacco Application (PMTA) process via a total programming approach, and/or provide select outsourced resources as required. Following FDA's extension of the PMTA compliance deadline, David rejoined NJOY as Chief Impact Officer. David is a graduate of Columbia University with a Master’s in Public Policy & Administration.

Gregory Doyle is a Chief Financial Officer at NJOY and is based in Greater New York City Area. He has worked as Senior Associate Consultant at The Lucas Group, MBA Candidate at The Wharton School, and Summer Associate at Moelis & Company. Gregory studied at Syracuse University between 2002 and 2006 and The Wharton School between 2010 and 2012.

Sean Molyneaux is an Executive Assistant To Chief Executive Officer at NJOY and is based in New York City, New York.